[Immunomodulator Cycloferon in the comprehensive treatment of patients with acute non-lymphoblastic leukemia].
The therapeutic benefit and action of the immunomodulator Cycloferon were evaluated in patients with acute non-lymphoblastic leukemia. When administered in conjunction with chemotherapy during first complete remission, it reduced both early-onset relapse frequency and degree of cytostatic-induced immune deficiency. The drug's action is mediated by changes taking place in cytokine and interferon synthesis.
Moiseev
S I
SI
Russian Research Institute of Hematology and Transfusiology, St. Petersburg.
Abdulkadyrov
K M
KM
Bubnova
L N
LN
Glazanova
T V
TV
Rozanova
O E
OE
Pavlova
I E
IE
Balashova
V A
VA
Kovalenko
A L
AL
D000166:Acridines / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000166:Acridines; D000276:Adjuvants, Immunologic; D007369:Interferon Inducers; C026430:10-carboxymethyl-9-acridanone